Atossa Genetics Inc. (NASDAQ:ATOS – Free Report) – Stock analysts at Zacks Research issued their Q2 2026 earnings estimates for Atossa Genetics in a research note issued on Wednesday, May 13th. Zacks Research analyst D. Bautz forecasts that the company will earn ($0.98) per share for the quarter. The consensus estimate for Atossa Genetics’ current full-year earnings is ($4.52) per share. Zacks Research also issued estimates for Atossa Genetics’ Q3 2026 earnings at ($1.02) EPS, Q4 2026 earnings at ($1.08) EPS, FY2026 earnings at ($4.19) EPS and FY2028 earnings at ($3.00) EPS.
Several other brokerages have also recently issued reports on ATOS. Ascendiant Capital Markets cut their price target on Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, April 10th. Weiss Ratings lowered Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. Finally, HC Wainwright lifted their price objective on Atossa Genetics to $25.00 and gave the company a “buy” rating in a report on Thursday, March 26th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, Atossa Genetics currently has an average rating of “Hold” and a consensus target price of $36.33.
Atossa Genetics Trading Down 0.2%
Shares of ATOS opened at $5.15 on Friday. Atossa Genetics has a 12 month low of $3.76 and a 12 month high of $19.35. The firm’s 50 day moving average is $5.27 and its 200-day moving average is $7.97. The stock has a market capitalization of $44.34 million, a PE ratio of -1.60 and a beta of 1.25.
Atossa Genetics (NASDAQ:ATOS – Get Free Report) last issued its quarterly earnings data on Friday, May 8th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.12).
Institutional Trading of Atossa Genetics
A number of institutional investors and hedge funds have recently made changes to their positions in ATOS. XTX Topco Ltd boosted its position in shares of Atossa Genetics by 581.2% during the 4th quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock worth $100,000 after acquiring an additional 144,412 shares in the last quarter. &PARTNERS acquired a new position in Atossa Genetics during the fourth quarter valued at approximately $25,000. Graham Capital Management L.P. lifted its stake in Atossa Genetics by 27.8% during the fourth quarter. Graham Capital Management L.P. now owns 211,369 shares of the company’s stock worth $125,000 after purchasing an additional 45,923 shares during the last quarter. State Street Corp boosted its holdings in shares of Atossa Genetics by 31.2% in the 4th quarter. State Street Corp now owns 596,485 shares of the company’s stock valued at $352,000 after purchasing an additional 141,990 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Atossa Genetics by 33.2% in the 4th quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock valued at $1,217,000 after purchasing an additional 514,175 shares in the last quarter. Institutional investors own 12.74% of the company’s stock.
About Atossa Genetics
Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.
The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.
Featured Articles
- Five stocks we like better than Atossa Genetics
- Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
- 2 Ways to Play the Big Pharma Patent Cliff
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
